Israel and GCC countries like the UAE are emerging as precision medicine hubs focusing on genomics, targeted therapies, and AI-based drug discovery. Israel’s Technion and UAE’s G42 Healthcare lead research in genomic sequencing and AI diagnostics.
Collaborations with US and European pharma giants bring clinical trials and biotech investments to the region. Regulatory reforms in the UAE enable fast-track drug approvals and telehealth integration, accelerating innovation.
Saudi Arabia invests in pharmaceutical industrial zones producing biosimilars and vaccines domestically, reducing import dependence and boosting regional health security.
